Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
J Infect Chemother. 2023 Apr;29(4):422-426. doi: 10.1016/j.jiac.2023.01.006. Epub 2023 Jan 20.
We investigated the occurrence of non-respiratory bacterial and fungal secondary infections, causative organisms, impact on clinical outcomes, and association between the secondary pathogens and mortality in hospitalized patients with coronavirus disease 2019 (COVID-19).
This was a retrospective cohort study that included data from inpatients with COVID-19 from multiple centers participating in the Japan COVID-19 Taskforce (April 2020 to May 2021). We obtained demographic, epidemiological, and microbiological data throughout the course of hospitalization and analyzed the cases of COVID-19 complicated by non-respiratory bacterial infections.
Of the 1914 patients included, non-respiratory bacterial infections with COVID-19 were diagnosed in 81 patients (4.2%). Of these, 59 (3.1%) were secondary infections. Bacteremia was the most frequent bacterial infection, occurring in 33 cases (55.9%), followed by urinary tract infections in 16 cases (27.1%). Staphylococcus epidermidis was the most common causative organism of bacteremia. Patients with COVID-19 with non-respiratory secondary bacterial infections had significantly higher mortality, and a multivariate logistic regression analysis demonstrated that those with bacteremia (aOdds Ratio = 15.3 [5.97-39.1]) were at higher risk of death. Multivariate logistic regression analysis showed that age, male sex, use of steroids to treat COVID-19, and intensive care unit admission increased the risk for nosocomial bacteremia.
Secondary bacteremia is an important complication that may lead to poor prognosis in cases with COVID-19. An appropriate medical management strategy must be established, especially for patients with concomitant predisposing factors.
本研究旨在调查 2019 年冠状病毒病(COVID-19)住院患者中非呼吸道细菌和真菌感染的发生情况、病原体、对临床结局的影响,以及继发性病原体与死亡率之间的关系。
这是一项回顾性队列研究,纳入了来自参与日本 COVID-19 工作组的多个中心的 COVID-19 住院患者数据(2020 年 4 月至 2021 年 5 月)。我们获取了患者在整个住院期间的人口统计学、流行病学和微生物学数据,并对 COVID-19 合并非呼吸道细菌感染的病例进行了分析。
在纳入的 1914 例患者中,有 81 例(4.2%)被诊断为 COVID-19 合并非呼吸道细菌感染,其中 59 例(3.1%)为继发感染。菌血症是最常见的细菌感染,发生于 33 例患者(55.9%),其次为尿路感染 16 例(27.1%)。凝固酶阴性葡萄球菌是菌血症最常见的病原体。COVID-19 合并非呼吸道继发性细菌感染患者的死亡率显著更高,多变量逻辑回归分析表明,发生菌血症的患者(优势比=15.3[5.97-39.1])死亡风险更高。多变量逻辑回归分析表明,年龄、男性、COVID-19 类固醇治疗和入住重症监护病房增加了医院获得性菌血症的风险。
继发性菌血症是 COVID-19 患者的一种重要并发症,可能导致预后不良。必须建立适当的医疗管理策略,特别是针对伴有合并症危险因素的患者。